Elizabeth A Burton, Victor Svenstrup, Mayank Murali, Hesam Dashti, Ruth J F Loos, Melina Claussnitzer
{"title":"Human Genetics of Adipose Dysfunction: Genomic Mechanisms and Therapeutic Opportunities in Cardiometabolic Disease.","authors":"Elizabeth A Burton, Victor Svenstrup, Mayank Murali, Hesam Dashti, Ruth J F Loos, Melina Claussnitzer","doi":"10.1161/ATVBAHA.126.324811","DOIUrl":null,"url":null,"abstract":"<p><p>Cardiometabolic diseases are a leading cause of global morbidity and mortality and arise from shared and distinct risk factors acting through interconnected biological pathways. Although excess adiposity is a major risk factor, body mass index incompletely captures cardiometabolic risk, reflecting heterogeneity in overall and regional fat storage capacity and ectopic lipid accumulation. Failure of subcutaneous adipose tissue to expand appropriately promotes lipid overflow into visceral and ectopic depots, contributing to insulin resistance, dyslipidemia, and organ dysfunction. Human genetic studies have identified thousands of genetic loci influencing fat storage, fat distribution, and ectopic lipid accumulation, revealing that these traits reflect distinct underlying mechanisms with divergent cardiometabolic consequences. Recent scaling of genetic discovery for refined adiposity and cardiometabolic phenotypes and multitrait genetic approaches have advanced understanding of adipose-driven disease heterogeneity. We highlight variant-to-function strategies to resolve causal pathways and discuss emerging scalable approaches to accelerate biological learning from genetic discovery and translate these insights into adipose-directed therapeutics for cardiometabolic disease.</p>","PeriodicalId":8401,"journal":{"name":"Arteriosclerosis, Thrombosis, and Vascular Biology","volume":" ","pages":""},"PeriodicalIF":8.8000,"publicationDate":"2026-10-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13693540/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Arteriosclerosis, Thrombosis, and Vascular Biology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1161/ATVBAHA.126.324811","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"HEMATOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Cardiometabolic diseases are a leading cause of global morbidity and mortality and arise from shared and distinct risk factors acting through interconnected biological pathways. Although excess adiposity is a major risk factor, body mass index incompletely captures cardiometabolic risk, reflecting heterogeneity in overall and regional fat storage capacity and ectopic lipid accumulation. Failure of subcutaneous adipose tissue to expand appropriately promotes lipid overflow into visceral and ectopic depots, contributing to insulin resistance, dyslipidemia, and organ dysfunction. Human genetic studies have identified thousands of genetic loci influencing fat storage, fat distribution, and ectopic lipid accumulation, revealing that these traits reflect distinct underlying mechanisms with divergent cardiometabolic consequences. Recent scaling of genetic discovery for refined adiposity and cardiometabolic phenotypes and multitrait genetic approaches have advanced understanding of adipose-driven disease heterogeneity. We highlight variant-to-function strategies to resolve causal pathways and discuss emerging scalable approaches to accelerate biological learning from genetic discovery and translate these insights into adipose-directed therapeutics for cardiometabolic disease.
期刊介绍:
The journal "Arteriosclerosis, Thrombosis, and Vascular Biology" (ATVB) is a scientific publication that focuses on the fields of vascular biology, atherosclerosis, and thrombosis. It is a peer-reviewed journal that publishes original research articles, reviews, and other scholarly content related to these areas. The journal is published by the American Heart Association (AHA) and the American Stroke Association (ASA).
The journal was published bi-monthly until January 1992, after which it transitioned to a monthly publication schedule. The journal is aimed at a professional audience, including academic cardiologists, vascular biologists, physiologists, pharmacologists and hematologists.